Stifel Reiterates Buy Rating on Braveheart Bio (BRVE) Sep 9, 2026 09:35AM
Cantor Fitzgerald Starts Braveheart Bio (BRVE) at Overweight Aug 31, 2026 06:37AM
TD Cowen Starts Braveheart Bio (BRVE) at Buy Aug 31, 2026 05:29AM
Stifel Starts Braveheart Bio (BRVE) at Buy Aug 31, 2026 02:50AM
Jefferies Starts Braveheart Bio (BRVE) at Buy Aug 31, 2026 02:49AM


Aug 31, 2026 02:04AM Goldman Sachs Starts Braveheart Bio (BRVE) at Buy
Aug 6, 2026 01:08PM Braveheart Bio shares surge 68% in New York trading debut
Aug 5, 2026 10:26AM Braveheart Bio reportedly pricing IPO above marketing range
Jul 30, 2026 06:19AM Braveheart Bio targets up to $318.8M in US IPO
Jul 15, 2026 06:06AM Braveheart Bio files for Nasdaq IPO under ticker BRVE